18F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy-Reference-Cited by-同舟云学术

18F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy

Published:2012-08-04 Issue:11 Volume:39 Page:1730-1736
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Bortot Daniel C.,Amorim Bárbara J.,Oki Glaucia C.,Gapski Sérgio B.,Santos Allan O.,Lima Mariana C. L.,Etchebehere Elba C. S. C.,Barboza Marycel F.,Mengatti Jair,Ramos Celso Dario

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-012-2195-8.pdf

Reference18 articles.

1. Nicolini A, Ferrari P, Sagripanti A, Carpi A. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Br J Cancer. 1999;79(9-10):1443–7. doi: 10.1038/sj.bjc.6690230 .

2. Talbot JN, Paycha F, Balogova S. Diagnosis of bone metastasis: recent comparative studies of imaging modalities. Q J Nucl Med Mol Imaging. 2011;55(4):374–410.

3. Ndlovu X, George R, Ellmann A, Warwick J. Should SPECT-CT replace SPECT for the evaluation of equivocal bone scan lesions in patients with underlying malignancies? Nucl Med Commun. 2010;31(7):659–65. doi: 10.1097/MNM.0b013e3283399107 .

4. Cook GJ, Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl Med. 2001;31(1):50–61.

5. Silberstein EB, Saenger EL, Tofe AJ, Alexander Jr GW, Park HM. Imaging of bone metastases with 99mTc-Sn-EHDP (diphosphonate), 18F, and skeletal radiography. A comparison of sensitivity. Radiology. 1973;107(3):551–5.

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial;The Lancet Oncology;2022-12

2. Whole-body tumor burden in PET/CT expert review;Clinical and Translational Imaging;2022-08-05

3. Comparison of 68Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer;European Journal of Hybrid Imaging;2022-03-01

4. Comparison of 18F-NaF Imaging, 99mTc-MDP Scintigraphy, and 18F-FDG for Detecting Bone Metastases;World Journal of Nuclear Medicine;2022-03

5. The effect of zoledronic acid and denosumab on the mandible and other bones: a 18F-NaF-PET study;Oral Radiology;2022-02-10